The Patent Finder

SBI Biotech Co., Ltd.

11 patents currently held · Updated Nov 16, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 2, 2027
    The maintenance fee for Methods of using anti-phospholipase D4 antibodies (US 10,336,834) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,470,992ANTI-ILT7 Antibody
In force
 · High confidence
In forceHigh confidence
US 8,084,585ANTI-ILT7 Antibody
In force
 · High confidence
In forceHigh confidence
US RE46,815Furanone derivative
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,688,992Inhibitory oligonucleotide and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,190,122Inhibitory oligonucleotide and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,336,834Methods of using anti-phospholipase D4 antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,730,955Polynucleotides encoding anti-human receptor-type protein tyrosine phosphatase sigma antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,803,026Anti-human receptor-type protein tyrosine phosphatase sigma antibody
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,944,715Anti-phospholipase D4 antibody
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,806,749TLR inhibitory oligonucleotides and their use
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 2 patents in force now held by others · 4 lapsed for an unpaid fee · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 abandoned · 4 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited